# Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma

> **NCT00132028** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 27 (actual)

## Conditions studied

- Adult Favorable Prognosis Hodgkin Lymphoma
- Adult Lymphocyte Depletion Hodgkin Lymphoma
- Adult Lymphocyte Predominant Hodgkin Lymphoma
- Adult Mixed Cellularity Hodgkin Lymphoma
- Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma
- Adult Nodular Sclerosis Hodgkin Lymphoma
- Adult Unfavorable Prognosis Hodgkin Lymphoma
- Recurrent Adult Hodgkin Lymphoma

## Interventions

- **DRUG:** vorinostat
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00132028
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2014-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00132028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00132028, "Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00132028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*